SCHEMBL7231111

SCHEMBL7231111

Nc1c(Cl)ccc2[nH]c(Cc3nc4c(N)c(Cl)ccc4[nH]3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.43
GAA P10253 3/20 0.43
RAB9A P51151 3/20 0.43
ALDH1A1 P00352 2/20 0.43
F10 P00742 4/20 0.39
LCK P06239 1/20 0.38
TPSAB1 Q15661 3/20 0.34
MAPT P10636 3/20 0.34
PRSS1 P07477 2/20 0.34
KDM4E B2RXH2 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
CACNA1B Q00975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6994906 0.98 GAA (0.42) NPC1GAARAB9AALDH1A1F10
SCHEMBL6363251 0.72 HPGD (0.45) NPC1GAARAB9AALDH1A1MAPT
SCHEMBL6998858 0.72 RIPK1 (0.37) NPC1GAARAB9AALDH1A1LCK
SCHEMBL5738360 0.71 NPC1 (0.37) NPC1GAARAB9AALDH1A1F10
SCHEMBL6994637 0.70 CHEK1 (0.56) NPC1GAARAB9AALDH1A1F10
Hydrochloric Acid SCHEMBL23497511 0.68 CACNA1H (0.36) NPC1GAARAB9AALDH1A1LCK
SCHEMBL6995563 0.67 F10 (0.44) NPC1GAARAB9AF10MAPT
Hydrochloric Acid SCHEMBL7004333 0.67 F10 (0.43) NPC1GAARAB9AF10MAPT
SCHEMBL5738314 0.64 PSMB8 (0.51) NPC1GAARAB9ALCKSMN1; SMN2
SCHEMBL7045259 0.64 NUDT1 (0.60) NPC1GAARAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541486-B1 Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation. ELAN PHARMA INTERNATIONAL LTD. (IE) 2003-04-01 US disclosed